Skip to main content
SpringerLink
Log in

Pharmacotherapy for Nocturia

  • Chapter
  • First Online:
Contemporary Pharmacotherapy of Overactive Bladder

  • 495 Accesses

Abstract

This chapter presents the current state of knowledge of the pharmacotherapy of nocturia. An overview of the diagnostic evaluation is followed by discussion of the indications and efficacy of different classes of medications used to treat nocturia. Nocturia, defined as voiding that occurs during the hours of sleep, is common and bothersome. The underlying causes are multiple and diverse. Determining the underlying etiology is essential for choosing the appropriate therapy. Pharmacologic treatment should be guided by a thorough clinical evaluation and data derived from a frequency-volume chart. Possible medications include those for overactive bladder (OAB), those for benign prostatic hyperplasia, and those to reduce nocturnal urine production. A systematic approach is essential for the optimal treatment of nocturia. In the absence of nocturnal polyuria, medications for BPH or overactive bladder may be employed. NP is highly prevalent among patients with nocturia, however, and antidiuretic therapy should be considered when measures to address serious underlying etiologic conditions are ineffective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):179–83.

    Google Scholar 

  2. Fitzgerald MP, Litman HJ, Link CL, McKinlay JB, Survey Investigators BACH. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol. 2007;177(4):1385–9.

    Article  PubMed  Google Scholar 

  3. Bosch JL, Weiss JP. The prevalence and causes of nocturia. J Urol. 2010;184(2):440–6. Review.

    Article  PubMed  Google Scholar 

  4. Tikkinen KA, Auvinen A, Johnson TM, Weiss JP, Keränen T, Tiitinen A, et al. A systematic evaluation of factors associated with nocturia—the population-based FINNO study. Am J Epidemiol. 2009;170(3):361–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J. 1983;287(6406):1665–7.

    Article  CAS  Google Scholar 

  6. Hofmeester I, Kollen BJ, Steffens MG, Bosch JL, Drake MJ, Weiss JP, et al. Impact of the International Continence Society (ICS) report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. 2015;115(4):520–36.

    Article  PubMed  Google Scholar 

  7. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Ruud Bosch JL. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol. 2000;164(4):1201–5.

    Article  CAS  PubMed  Google Scholar 

  8. Weiss JP. Prevalence of nocturnal polyuria in nocturia. J Urol. 2009;181((4):538.

    Article  Google Scholar 

  9. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991;229(2):131–4.

    Article  CAS  PubMed  Google Scholar 

  10. Yalkut D, Lee LY, Grider J, Jorgensen M, Jackson B, Ott C. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med. 1996;128(3):322–8.

    Article  CAS  PubMed  Google Scholar 

  11. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson KE, Wein AJ. Pharmacologic management of lower urinary tract storage and emptying failure. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 1836–74.

    Google Scholar 

  13. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243.

    Article  CAS  PubMed  Google Scholar 

  14. Dmochowski R, Wein AJ. Lower urinary tract pharmacotherapy for nocturia. In: Weiss JP, Blaivas JG, Van Kerrebroeck P, Wein AJ, editors. Nocturia: causes, consequences and clinical approaches. New York: Springer Science+Business Media; 2012. p. 127–34.

    Chapter  Google Scholar 

  15. Brubaker L, Fitzgerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(7):737–41.

    Article  PubMed  Google Scholar 

  16. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analysis. Eur Urol. 2012;62(6):1040–60.

    Article  CAS  PubMed  Google Scholar 

  17. Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J. 2010;21(7):847–54.

    Article  PubMed  Google Scholar 

  18. Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Ishizuka O, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol. 2011;86(1):170–4.

    Article  Google Scholar 

  19. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. J Urol. 2007;178(6):2488–94.

    Article  CAS  PubMed  Google Scholar 

  20. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. BJU Int. 2010;105(1):58–66.

    Article  CAS  PubMed  Google Scholar 

  21. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Frost HT, Massow U, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–12.

    Article  CAS  PubMed  Google Scholar 

  22. Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Siami P, Staskin DR. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62–8.

    Article  PubMed  Google Scholar 

  23. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–6.

    Article  PubMed  Google Scholar 

  24. Zinner N, Gittelmen M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase II trial. J Urol. 2004;171(6 Pt 1):2311–5.

    Article  PubMed  Google Scholar 

  25. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275–80.

    Article  PubMed  Google Scholar 

  26. Tikkinen KA, Johnson TM, Tammela TL, Sintonen H, Haukka J, Huhtala H, Auvinen A. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010;57(3):488–96.

    Article  PubMed  Google Scholar 

  27. Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992;6(3):832–9.

    Article  CAS  PubMed  Google Scholar 

  28. Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, Arai Y. Nocturia and benign prostatic hyperplasia. Urology. 2003;61(4):786–90.

    Article  PubMed  Google Scholar 

  29. Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl. 2005;4(2):61–8.

    Article  CAS  Google Scholar 

  30. Speakman M. Efficacy and safety of tamsulosin OCAS. BJU Int. 2006;98(Suppl 2):13–7.

    Article  CAS  Google Scholar 

  31. Bliwise DL, Holm-Larsen T, Goble S, Norgaard JP. Short time to first void is associated with lower whole-night sleep quality in nocturia patients. J Clin Sleep Med. 2015;11(1):53–5.

    PubMed  PubMed Central  Google Scholar 

  32. Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol. 2003;170(1):145–8.

    Article  PubMed  Google Scholar 

  33. Johnson TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178(5):2045–51.

    Article  CAS  PubMed  Google Scholar 

  34. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92(3):257–61.

    Article  CAS  PubMed  Google Scholar 

  35. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E, European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.

    Article  PubMed  Google Scholar 

  36. Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323(1):202–9.

    Article  CAS  PubMed  Google Scholar 

  37. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.

    Article  CAS  PubMed  Google Scholar 

  38. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274–9.

    Article  CAS  PubMed  Google Scholar 

  39. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.

    Article  CAS  PubMed  Google Scholar 

  40. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewaki P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.

    Article  CAS  PubMed  Google Scholar 

  41. Hammer M, Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide hormone analogue, desmopressin. J Pharmacol Exp Ther. 1985;234(3):754–60.

    CAS  PubMed  Google Scholar 

  42. Vilhardt H. Basic pharmacology of desmopressin. Drug Invest. 1990;2(Suppl 5):2.

    Article  Google Scholar 

  43. Sands JM. Molecular mechanisms of urea transport. J Membr Biol. 2003;191(3):149–63.

    Article  CAS  PubMed  Google Scholar 

  44. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.

    Article  CAS  PubMed  Google Scholar 

  45. Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Bosch JLHR, Gacci M, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017;72(5):757–69.

    Article  PubMed  Google Scholar 

  46. Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441–7.

    Article  CAS  PubMed  Google Scholar 

  47. Van Kerrebroeck P. Nocturia and antidiuretic therapy. In: Weiss JP, Blaivas JG, Van Kerrebroeck P, Wein AJ, editors. Nocturia: causes, consequences and clinical approaches. New York: Springer Science+Business Media; 2012. p. 135–44.

    Chapter  Google Scholar 

  48. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int. 2002;89(9):855–62.

    Article  CAS  PubMed  Google Scholar 

  49. Lose G, Lalos O, Freeman RM, Van Kerrebroeck P, Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003;189(4):1106–13.

    Article  CAS  PubMed  Google Scholar 

  50. Van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study. Eur Urol. 2007;52(1):221–9.

    Article  PubMed  Google Scholar 

  51. Lose G, Mattiasson A, Walter S, Lalos O, Van Kerrebroeck P, Abrams P, Freeman R. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021–5.

    Article  CAS  PubMed  Google Scholar 

  52. Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, Abrams S, Cheng M, Wein A. Efficacy and safety of SER120 nasal spray in nocturia patients pooled analysis of 2 randomized, double-blind, placebo-controlled phase 3 trials. J Urol. 2018; https://doi.org/10.1016/j.juro.2018.04.050. Article in Press.

    Article  CAS  Google Scholar 

  53. Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013;5(6):310–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Smith Institute for Urology, Greenlawn, NY, USA

    Ari M. Bergman

  2. Department of Urology, SUNY Downstate Medical Center, Brooklyn, NY, USA

    Jeffrey P. Weiss

Authors
  1. Ari M. Bergman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey P. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ari M. Bergman .

Editor information

Editors and Affiliations

  1. Department of Urology, Medical University of South Carolina, Charleston, SC, USA

    Lindsey Cox

  2. Department of Urology, Medical University of South Carolina, Charleston, SC, USA

    Eric S. Rovner

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bergman, A.M., Weiss, J.P. (2019). Pharmacotherapy for Nocturia. In: Cox, L., Rovner, E. (eds) Contemporary Pharmacotherapy of Overactive Bladder. Springer, Cham. https://doi.org/10.1007/978-3-319-97265-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97265-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97264-0

  • Online ISBN: 978-3-319-97265-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation